As 2012 is coming to an end and we are all getting ready for the festive season (the freezing weather outside just proves that it's time for Christmas), I thought I would share with you some of the highlights of the year (as chosen by your preference).
Earlier this year we decided to venture into the world of ebooks. Having access to such amazing in depth content through our World Vaccine Congress series, as well as our network of vaccine stakeholders and industry friends, it seemed like a waste not to share these insights with our community. Thanks to the hard work and dedication of the whole team, we managed to pull together information that you found useful, interesting and enjoyed. So here are the top 5 vaccine ebooks for 2012:
1. Influenza vaccine ebook:
In spite of the various challenges, the future of the influenza vaccine industry looks positive, with increasing public awareness and several promising influenza vaccines in the pipeline. However, the biotech and pharmaceutical companies cannot do it alone; the influenza vaccine market will only be able to grow with the help of contract manufacturing organizations, contract research organizations, clinical trial organizations, consultants and banks, and others. We look forward to seeing all that can be accomplished through these future partnerships.
2. Cancer vaccine ebook:
Unlike chemotherapy and radiation therapy, cancer vaccines have very few side effects; traditional treatmentsâ€”including surgery, radiation, and chemotherapyâ€”are aggressive approaches that can have detrimental side effects, whereas vaccines encourage the body to heal itself. This form of treatment has many advantages.
3. Allergy vaccine ebook:
The prevalence of allergic diseases is global and growing. Recent trends indicate that half of all Europeans will suffer from allergy by 2015. Today, allergy treatment, which only suppresses the symptoms or lessens the inflammation, is via drugs, anti-histamines or steroids. And that market is big business. The anti-allergy drug market is anticipated to exceed $14.7 billion by 2015 in the US alone. Worldwide allergy vaccine sales were $642 million in 2010.
4. Vaccine Contract Research A look at the next biggest markets for CROs – Who's next after China and India?
Over the past 10 years, CROs have raised their levels of services and become more sophisticated operations. They're becoming the place where expertise resides. In fact, 2010 marked the first time employment at CROs exceeded those at major pharmas on the clinical side, according to a study conducted by Tufts CSDD. Some 46,550 worked in clinical at CROs and 41,275 worked in clinical at major pharmas. As the outsourcing market continues to grow, so has the number of attractive locations for clinical trials. Smaller countries have joined the usual suspects-such as China and India on the CRO map.
5. Vaccine CMO selection
Choosing the correct CMO partner is key to the success of the vaccine development and in this eBook we will explore what pharma and biotech are looking for in a CMO and how they select their partners. Do you need to know how pharmaceutical companies decide which CMO to use? Then this eBook is for you!
I am currently working on 3 more that will be published early next year – one on HIV vaccines, one on NID vaccines and one on the vaccine market size/opportunities in Europe and the US. If you would like to contribute or have any ideas as per the content, please get in touch through the comment box below.
Don't forget to check out the top 20 downloaded presentations from 2012 as well here.